相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Epigenetic biomarkers in skin cancer
Edward S. Greenberg et al.
CANCER LETTERS (2014)
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours
K. G. Griewank et al.
BRITISH JOURNAL OF CANCER (2013)
Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice
L. Heinzerling et al.
BRITISH JOURNAL OF CANCER (2013)
Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11
A. E. Koopmans et al.
BRITISH JOURNAL OF CANCER (2013)
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
Fernando Ulloa-Montoya et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma
Graham J. Mann et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma
Wesley O. Greaves et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2013)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors
Katherine L. Jameson et al.
NATURE MEDICINE (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells
Jason R. Todd et al.
PIGMENT CELL & MELANOMA RESEARCH (2013)
TERT Promoter Mutations in Familial and Sporadic Melanoma
Susanne Horn et al.
SCIENCE (2013)
Highly Recurrent TERT Promoter Mutations in Human Melanoma
Franklin W. Huang et al.
SCIENCE (2013)
Elucidating Distinct Roles for NF1 in Melanomagenesis
Ophelia Maertens et al.
CANCER DISCOVERY (2013)
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Steven R. Whittaker et al.
CANCER DISCOVERY (2013)
GNAQ and GNA11 mutations in melanocytomas of the central nervous system
Rajmohan Murali et al.
ACTA NEUROPATHOLOGICA (2012)
A Proposal for Improving Multicolor FISH Sensitivity in the Diagnosis of Malignant Melanoma Using New Combined Criteria
Katrin Kerl et al.
AMERICAN JOURNAL OF DERMATOPATHOLOGY (2012)
A Distinct Subset of Atypical Spitz Tumors is Characterized by BRAF Mutation and Loss of BAP1 Expression
Thomas Wiesner et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
A Highly Specific and Discriminatory FISH Assay for Distinguishing Between Benign and Malignant Melanocytic Neoplasms
Pedram Gerami et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Enhanced Detection of Spitzoid Melanomas Using Fluorescence In Situ Hybridization With 9p21 as an Adjunctive Probe
Bryan Gammon et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study
S. Thomas et al.
BRITISH JOURNAL OF CANCER (2012)
Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors
Y. Xu et al.
BRITISH JOURNAL OF CANCER (2012)
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
R. M. Anforth et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
NRAS mutation status is an independent prognostic factor in metastatic melanoma
John A. Jakob et al.
CANCER (2012)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
Sunitinib Therapy for Melanoma Patients with KIT Mutations
David R. Minor et al.
CLINICAL CANCER RESEARCH (2012)
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies et al.
CLINICAL CANCER RESEARCH (2012)
BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration
Ross J. Flockhart et al.
GENOME RESEARCH (2012)
Fluorescence in situ hybridization for the differential diagnosis between Spitz naevus and spitzoid melanoma
Celia Requena et al.
HISTOPATHOLOGY (2012)
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration
Jin Hyun Cho et al.
INVESTIGATIONAL NEW DRUGS (2012)
Major Response to Everolimus in Melanoma With Acquired Imatinib Resistance
Lu Si et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Review and Cross-Validation of Gene Expression Signatures and Melanoma Prognosis
Sarah-Jane Schramm et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
James S. Wilmott et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Melanoma molecular classes and prognosis in the postgenomic era
Elisa Tremante et al.
LANCET ONCOLOGY (2012)
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET ONCOLOGY (2012)
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante et al.
LANCET ONCOLOGY (2012)
An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background
Devarati Mitra et al.
NATURE (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing
Mitchell S. Stark et al.
NATURE GENETICS (2012)
BAP1 loss defines a new class of renal cell carcinoma
Samuel Pena-LlopiS et al.
NATURE GENETICS (2012)
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Michael Krauthammer et al.
NATURE GENETICS (2012)
Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization
Viktoria Lazar et al.
MELANOMA RESEARCH (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Novel Somatic Mutations to PI3K Pathway Genes in Metastatic Melanoma
Austin Y. Shull et al.
PLOS ONE (2012)
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
Hubing Shi et al.
NATURE COMMUNICATIONS (2012)
12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
Jane L. Messina et al.
SCIENTIFIC REPORTS (2012)
HIV-1 Antiretroviral Drug Therapy
Eric J. Arts et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
High Throughput Mass Spectrometry-Based Mutation Profiling of Primary Uveal Melanoma
Anthony B. Daniels et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2012)
Assessment of Copy Number Status of Chromosomes 6 and 11 by FISH Provides Independent Prognostic Information in Primary Melanoma
Jeffrey P. North et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
A Phase 2 Trial of Dasatinib in Advanced Melanoma
Harriet M. Kluger et al.
CANCER (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
Julie A. Ellerhorst et al.
CLINICAL CANCER RESEARCH (2011)
Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma
Yan Kong et al.
CLINICAL CANCER RESEARCH (2011)
KIT as a Therapeutic Target in Metastatic Melanoma
Richard D. Carvajal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification
Jun Guo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
Mohamed H. Abdel-Rahman et al.
JOURNAL OF MEDICAL GENETICS (2011)
Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases
Beatrice Vergier et al.
MODERN PATHOLOGY (2011)
EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression
Tao Fan et al.
MOLECULAR CANCER RESEARCH (2011)
Tumour evolution inferred by single-cell sequencing
Nicholas Navin et al.
NATURE (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma
Satoru Yokoyama et al.
NATURE (2011)
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
Corine Bertolotto et al.
NATURE (2011)
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew Bott et al.
NATURE GENETICS (2011)
Exome sequencing identifies GRIN2A as frequently mutated in melanoma
Xiaomu Wei et al.
NATURE GENETICS (2011)
Germline mutations in BAP1 predispose to melanocytic tumors
Thomas Wiesner et al.
NATURE GENETICS (2011)
Germline BAP1 mutations predispose to malignant mesothelioma
Joseph R. Testa et al.
NATURE GENETICS (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site
Juergen Bauer et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Molecular Profiling of Melanoma and the Evolution of Patient-Specific Therapy
Thomas F. Gajewski
SEMINARS IN ONCOLOGY (2011)
SWI/SNF nucleosome remodellers and cancer
Boris G. Wilson et al.
NATURE REVIEWS CANCER (2011)
Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system
Heidi V. N. Kusters-Vandevelde et al.
ACTA NEUROPATHOLOGICA (2010)
Sensitivity of Fluorescence In Situ Hybridization for Melanoma Diagnosis Using RREB1, MYB, Cep6, and 11q13 Probes in Melanoma Subtypes
Pedram Gerami et al.
ARCHIVES OF DERMATOLOGY (2010)
SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells
Jiri Vachtenheim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma
Jill C. Rubinstein et al.
BMC MEDICAL GENOMICS (2010)
Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival
Geoffrey Y. Ku et al.
CANCER (2010)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome
Michael Holzel et al.
CELL (2010)
A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth
Alexander Roesch et al.
CELL (2010)
Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?
Jozsef Timar et al.
CLINICAL & EXPERIMENTAL METASTASIS (2010)
Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome
Goran Jonsson et al.
CLINICAL CANCER RESEARCH (2010)
SWItching on the transcriptional circuitry in melanoma
Srinivas Vinod Saladi et al.
EPIGENETICS (2010)
Somatic Alterations in the Melanoma Genome: A High-Resolution Array-Based Comparative Genomic Hybridization Study
Andreas Gast et al.
GENES CHROMOSOMES & CANCER (2010)
Inferring tumor progression from genomic heterogeneity
Nicholas Navin et al.
GENOME RESEARCH (2010)
Methylation of PTEN as a Prognostic Factor in Malignant Melanoma of the Skin
Christoph Lahtz et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB
Johanna C. Scheuermann et al.
NATURE (2010)
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Peter J. Campbell et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Shinichi Yachida et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mutations in GNA11 in Uveal Melanoma.
Catherine D. Van Raamsdonk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure
Despina Handolias et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
Genetic and morphologic features for melanoma classification
Sigrid M. C. Broekaert et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
J. William Harbour et al.
SCIENCE (2010)
Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies
Steven Whittaker et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers
Ping Chi et al.
NATURE REVIEWS CANCER (2010)
Fluorescence In Situ Hybridization (FISH) as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma
Pedram Gerami et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
Tumor Self-Seeding by Circulating Cancer Cells
Mi-Young Kim et al.
CELL (2009)
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
Scott E. Woodman et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Catherine D. Van Raamsdonk et al.
NATURE (2009)
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Todd D. Prickett et al.
NATURE GENETICS (2009)
BrafV600E cooperates with Pten loss to induce metastatic melanoma
David Dankort et al.
NATURE GENETICS (2009)
A germline mutation of p14/ARF in a melanoma kindred
Zaida Garcia-Casado et al.
MELANOMA RESEARCH (2009)
Functions and Regulatory Mechanisms of Gq-Signaling Pathways
Norikazu Mizuno et al.
NEUROSIGNALS (2009)
Phase II trial of imatinib mesylate in patients with metastatic melanoma
K. B. Kim et al.
BRITISH JOURNAL OF CANCER (2008)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization
Karen H. Ventii et al.
CANCER RESEARCH (2008)
Integrative genomic analysis of aneuploidy in uveal melanoma
Justis P. Ehlers et al.
CLINICAL CANCER RESEARCH (2008)
Predicting clinical outcome through molecular profiling in stage III melanoma
Thomas John et al.
CLINICAL CANCER RESEARCH (2008)
MC1R variants, melanoma and red hair color phenotype: A meta-analysis
Sara Raimondi et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Major response to imatinib mesylate in KIT-mutated melanoma
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Heterogeneity of kinase inhibitor resistance mechanisms in GIST
B. Liegl et al.
JOURNAL OF PATHOLOGY (2008)
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma
Ingeborg M. Bachmann et al.
MODERN PATHOLOGY (2008)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S. M. Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding et al.
NATURE (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
Jose Lutzky et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Improving melanoma classification by integrating genetic and morphologic features
Amaya Viros et al.
PLOS MEDICINE (2008)
MC1R variants associated susceptibility to basal cell carcinoma of skin:: Interaction with host factors and XRCC3 polymorphism
Dominique Scherer et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
How to make a melanoma: what do we know of the primary clonal events?
Dorothy C. Bennett
PIGMENT CELL & MELANOMA RESEARCH (2008)
Genetics: What advice for patients who present with a family history of melanoma?
Julia A. Newton Bishop et al.
SEMINARS IN ONCOLOGY (2007)
The genomic landscapes of human breast and colorectal cancers
Laura D. Wood et al.
SCIENCE (2007)
Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family:: Identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF
Eric Pasmant et al.
CANCER RESEARCH (2007)
Distinct clinical and pathological features are associated with the BRAF T1799A(V600E) mutation in primary melanoma
Wendy Liu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents
Alisa M. Goldstein et al.
JOURNAL OF MEDICAL GENETICS (2007)
G-protein-coupled receptors and cancer
Robert T. Dorsam et al.
NATURE REVIEWS CANCER (2007)
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Somatic activation of KIT in distinct subtypes of melanoma
John A. Curtin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Malignant melanoma: genetics and therapeutics in the genomic era
Lynda Chin et al.
GENES & DEVELOPMENT (2006)
MC1R germline variants confer risk for BRAF-mutant melanoma
Maria Teresa Landi et al.
SCIENCE (2006)
Epigenetic silencing of the PTEN gene in melanoma
Alireza Mirmohammadsadegh et al.
CANCER RESEARCH (2006)
Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma - Significant toxicity with no clinical efficacy
K Wyman et al.
CANCER (2006)
Gene expression profiling of primary cutaneous melanoma and clinical outcome
VR Winnepenninckx et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Population-based prevalence of CDKN2A mutations in Utah melanoma families
Mark J. Eliason et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Cell signalling diversity of the Gqα family of heterotrimeric G proteins
KB Hubbard et al.
CELLULAR SIGNALLING (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A mutation hotspot at the p14ARF splice site
M Harland et al.
ONCOGENE (2005)
The NF1 tumor suppressor critically regulates TSC2 and mTOR
CM Johannessen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
CR Antonescu et al.
CLINICAL CANCER RESEARCH (2005)
Lack of clinical efficacy of imatinib in metastatic melanoma
S Ugurel et al.
BRITISH JOURNAL OF CANCER (2005)
Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors
B Dasgupta et al.
CANCER RESEARCH (2005)
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors
LL Chen et al.
CANCER RESEARCH (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death
MD Onken et al.
CANCER RESEARCH (2004)
High frequency of BRAF mutations in nevi
PM Pollock et al.
NATURE GENETICS (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Molecular classification of cutaneous malignant melanoma by gene expression profiling
M Bittner et al.
NATURE (2000)
分享论文
